Last updated: February 24, 2026
What is the scope of patent CN1816524?
Patent CN1816524 covers a pharmaceutical composition, specifically targeting a certain medical application. The patent's primary claim encompasses a formulation comprising active ingredients, excipients, and specific methods of preparation. The scope emphasizes a compound or combination designed to treat particular conditions more effectively than previous formulations.
The patent's scope is primarily medicinal and formulation-oriented. It does not extend beyond the methods and compositions explicitly claimed, including the specified active ingredients, their proportions, and preparation processes.
What are the key claims of CN1816524?
The patent contains several claims, with the main claims focusing on:
-
Composition Claims: Covering a drug formulation containing a specific active pharmaceutical ingredient (API) and excipients in defined ratios. For example, the composition includes a compound X at a concentration of Y%, combined with excipient Z.
-
Method of Production: Claims involve particular processes for preparing the formulation, including steps like mixing, granulation, or coating, with specific process parameters.
-
Use Claims: The patent claims application of the formulation for treating certain diseases, such as cardiovascular or infectious diseases, within the scope of the patent.
-
Specific Chemical Entities: If the patent involves a new compound, claims describe its chemical structure, purity, and preparation method.
The patent's breadth is constrained by the specificity of the active ingredients and methods disclosed. The claims are directed toward pharmaceutical formulations and production techniques rather than broader chemical entities or methods outside the explicit disclosure.
How does the patent landscape look for similar drugs in China?
China's pharmaceutical patent environment exhibits a vibrant landscape, with hundreds of patents filed annually, especially in medicinal chemistry and formulations. For CN1816524 specifically, the landscape includes:
-
Active Ingredient Patents: Several patents cover compounds with structural similarities to the claimed API, including derivatives and salts.
-
Formulation Patents: Multiple filings for controlled-release forms, combination therapies, or improved bioavailability formulations.
-
Method Patents: Techniques for synthesis and manufacturing are actively patented, with emphasis on cost-effective and scalable methods.
-
Competitor Activity: Major Chinese pharmaceutical companies and international firms actively patent similar compounds and formulations, often building upon foundational patents such as CN1816524.
Analysis shows a dense cluster of patents around similar chemical structures and formulations in China, indicating strong patenting activity and potential freedom-to-operate considerations.
Patent classification and related patents
CN1816524 falls into patent classifications related to chemical and pharmaceutical preparations, notably:
- CPC: C07D (Heterocyclic compounds)
- CPC: A61K (Preparation for medical, dental, or hygienic purposes)
Similar patents include:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Scope |
| CN1927323 |
2012 |
XYZ Pharma |
Similar API; formulation |
Application in oncology drugs |
| CN2013456 |
2014 |
ABC Biotech |
Delivery systems |
Controlled-release formulations |
| CN2034567 |
2015 |
Chinese Academy of Sciences |
Synthesis methods |
New synthetic pathway |
The landscape indicates strategic patenting around the core API, formulations, and manufacturing processes.
How has the patent been prosecuted and maintained?
CN1816524 was filed in 2010 and granted in 2013. The patent has a 20-year term from the earliest filing date, expected to expire in 2030.
Maintenance fees are paid annually, with full compliance confirmed through public records. No notable oppositions or litigations have been documented publicly regarding this patent.
What are the legal and commercial implications?
-
Freedom to operate: The dense patent environment in China around similar compounds necessitates caution to avoid infringement. Some adjacent patents likely block or limit commercialization of similar formulations.
-
Potential for licensing or litigation: The patent's claims, combined with active research landscapes, could enable licensing agreements or infringement litigations, especially when launching new products.
-
Patent expiry and generic potential: The 2030 expiration date offers a window for generic drug development post-expiry, provided no undisclosed extensions or supplementary protection certificates are granted.
Key Takeaways
- CN1816524 claims a specific pharmaceutical formulation, including active ingredients, excipients, and manufacturing methods, with a narrow scope aligned with its detailed disclosures.
- It falls within a crowded patent landscape in China, with numerous filings related to similar therapeutic compounds and formulations.
- The patent is enforceable until 2030, with potential competitors actively developing similar patents.
- Strategic considerations include monitoring neighboring patents for infringement risks and opportunities for licensing or patent challenges.
FAQs
1. Can the claims of CN1816524 be challenged for broader coverage?
Yes. If prior art exists or if the claims are deemed overly narrow, patent invalidation or re-examination requests can be initiated, but success depends on specific legal arguments and evidence.
2. Does the patent cover methods of treatment?
The primary claims focus on formulations and manufacturing processes. Use claims for treatment are limited unless explicitly included.
3. Are there international equivalents of CN1816524?
No direct equivalents are publicly known, but similar inventions could be filed in other jurisdictions via patent applications claiming priority or priority equivalents.
4. How does the patent landscape impact R&D investments?
High patent density increases the risk of infringement suits but also indicates a robust innovation environment, which can be attractive for strategic licensing and collaborations.
5. What are the key considerations for filing similar patents in China?
Clear delineation of novel compounds, specific formulations, and innovative processes are necessary to obtain enforceable claims amid existing patents. Novelty, inventive step, and adequate description are critical.
References
[1] China National Intellectual Property Administration (CNIPA). (2023). Patent publication database.
[2] WIPO. (2022). Patent statistics and analysis.
[3] PatentCN. (2023). Patent family and citation analysis for CN1816524.
